Compare Tango Therapeutics Inc. (TNGX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs T Rowe Price Group Inc — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while T Rowe Price Group Inc trades at $99.49 (market cap $21.63B). The key difference: T Rowe Price Group Inc is far larger — about 5.8× Tango Therapeutics Inc.'s market cap, and T Rowe Price Group Inc pays a 5.13% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and T Rowe Price Group Inc for 115 Days on average.
| TNGX | TROW | |
|---|---|---|
Market Cap | $3.75B | $21.63B |
Volume | 9,619,106 | 2,302,405 |
Sector | Health | Financials |
52-Week High | $32.90 | $121.68 |
52-Week Low | $7.50 | $86.19 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $2.77B | $18.82B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
T. Rowe Price (TROW) trades at $99.62, down 4.2% today, with a bearish technical signal despite strong fundamentals including a 29.26% net income margin and 20.1% ROE. The stock shows attractive valuation with a P/E of 10.18 and P/B of 1.97, while recent earnings beat expectations in Q1 and Q2 2026. Assets under management reached $1.90 trillion in August 2026 despite net outflows, and the company maintains a strong dividend history with 40 years of consecutive increases.
TROW presents a value opportunity with solid profitability and dividend stability, though technical weakness and mixed analyst sentiment (21% buy, 63% hold) suggest near-term caution. The consensus price target of $110.50 implies 11% upside potential, but investors face risks from market-sensitive revenue and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
